Global Visceral Leishmaniasis Market – Industry Trends and Forecast to 2029

Visceral Leishmaniasis Market Analysis and Size

The global visceral leishmaniasis market is expected to witness significant growth during the forecast period. According to the World Health Organization (WHO) records, around 50,000 to 90,000 new cases of visceral leishmaniasis occur worldwide in a year. The wide availability of numerous treatment options is attracting the government to make huge investments. Although leishmaniasis is dispersed in a way that affects some of the poorest population and is related to a lack of financial resources and malnutrition. Around 350 million people are considered at high risk of contracting the disease.  COVID-19 also had a major impact on the market growth.

Data Bridge Market Research analyses a growth rate in the g global visceral leishmaniasis market in the forecast period 2022-2029. The expected CAGR of global visceral leishmaniasis market is tend to be around 9% in the mentioned forecast period. The market was valued at USD 26.5 million in 2021, and it would grow upto USD 52.80 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Visceral Leishmaniasis Market Scope and Segmentation

Market Definition

Visceral leishmaniasis is also known as kala-azar and is the most common type of leishmaniasis, defined as protozoan parasites infections caused by leishmania. The typical signs and symptoms of this condition are irregular episodes of fever, gradual weight loss, swelling of the spleen and liver. The transmission is mostly due to unhygienic conditions, weak immune system, and malnutrition. Growing climatic changes and population mobility are the risk factors that are associated with the leishmaniasis disease.

Global Visceral Leishmaniasis Market Dynamics

Drivers

• Increase in Pathological Tests

Several pathological tests help diagnose the medical condition. Serological test dominated the market due to rising demand for pathological testing for the diagnosis of numerous infectious diseases. Parasitological evaluation is anticipated to witness major growth, as it is the standard test for an accurate disease diagnosis.  This boosts the growth of the market.

• Development of New Chemical Drugs

As per the data published in 2017, by Drugs for Neglected Diseases initiative (DNDi’), two new chemical entities (NCE) DNDI-6148 and DNDI-0690 are discovered into the preclinical development stage for the treatment of  visceral and cutaneous leishmaniasis in the year 2016. Immunomodulator- CpG-D35, is also in pre-clinical development stage, which will be used as an addition along with drug therapy to fight against cutaneous leishmaniasis. These new advances transform drug development into new treatment therapy in near future, which in turn is boosting the growth of leishmaniasis market.

Opportunities

• Rising Incidence of Visceral Leishmaniasis

According to the World Health Organization (WHO) records, around 7, 00,000 to 1 million new cases and 20,000 - 30,000 deaths occur globally each year due to leishmaniasis. Visceral leishmaniasis (VL) is the most severe condition among the other two forms of leishmaniasis. According to the WHO, approximately 50,000 to 90,000 new cases of visceral leishmaniasis were noted.  Thus, it boosts the market growth.

• Growing Agreements Between Organizations

Increasing agreements between several organizations is creating much opportunities for the market. For instance, In 2016, WHO and Gilead Sciences, Inc. signed an agreement to donate 3,80,400 vials of AmBisome (liposomal amphotericin B), thus extending their previous agreement from 2016 to 2021. The five-year collaboration and funding of US$ 20 million by Gilead Sciences, Inc. are projected to provide access to diagnosis and treatment for the population growth affected by visceral leishmaniasis in major endemic countries such as Ethiopia, Nepal, Bangladesh, India,South Sudan, and Sudan.

 Restraints/Challenges

• Limited Studies and Surveys

There are very limited studies and surveys that is hampering the growth of the market. Only a minimal amount of data are available with respect to the studies. A few studies mainly focused on groups from a single hospital wherein only a limited number of patients are observed. Thus, this hampers the growth of the market.

• High Cost

The treatment of Leishmaniasis is very high due to the expensive drugs. Apart from this, the drugs used for the treatment can also cause severe adverse effects. Although new treatment options are being developed, it is anticipated to give a huge extent of therapeutic measures against these diseases and decrease the side effects. This acts as a major hindrance for the market.

This global visceral leishmaniasis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global visceral leishmaniasis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Visceral Leishmaniasis Market         

COVID-19 has left an unparalleled global public health crisis that has impacted practically every business. Its long-term repercussions are expected to influence industry growth during the forecast period. The covid-19 outbreak negatively impacted the global economy and hurt the growth of the visceral leishmaniasis market because there was a drop in the demand for visceral leishmaniasis drugs and treatment because healthcare facilities all over the world were loaded with millions of Covid-19 positive patients. In the post-pandemic era, the market is expected to rise because of the availability of varied treatment options. 

Recent Development

• In February 2020, Novartis made an agreement with Drugs for neglected disease initiatives. It is a non-profit R&D organization to produce LXE408 intended for visceral leishmaniasis collaboratively.

Global Visceral Leishmaniasis Market Scope

The global visceral leishmaniasis market is segmented on the basis of disease type, treatment, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Disease Type

• Cutaneous Leishmaniasis
• Mucosal Leishmaniasis
• Visceral Leishmaniasis

Treatment

• Antiparasitic
• Antifungal
• Others

Route of Administration

• Oral
• Injectable
• Others

End User

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Online Pharmacy
• Retail Pharmacy

Visceral Leishmaniasis Market Regional Analysis/Insights

The global visceral leishmaniasis market is analysed and market size insights and trends are provided by disease type, treatment, route of administration, distribution channel and end-user as referenced above.

The major countries covered in the global visceral leishmaniasis market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America has been witnessing a positive growth for global visceral leishmaniasis market throughout the forecasted period due to the high adoption of visceral leishmaniasis drugs, presence of key generic players and increased patient awareness level as well as high prevalence of leishmaniasis.

Asia-Pacific dominates the market due to the presence of refined healthcare infrastructure.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Visceral Leishmaniasis Market Share Analysis

The global visceral leishmaniasis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global visceral leishmaniasis market.

Key players operating in the global visceral leishmaniasis market include:

• Novartis AG (Switzerland)
• Endo International Inc (Ireland)
• Teva Pharmaceutical Industries Ltd (Israel)
• Glenmark Pharmaceuticals Ltd (India)
• Cipla Inc (India)
• Dr Reddy's Laboratories Ltd (India)
• Abbott (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Pfizer Inc (U.S.)
• Zydus Group (India)
• Lupin (India)
• Amorphex Therapeutics Holdings, Inc (U.S.)
• Bausch Health Companies Inc. (Canada)

SKU-54245